Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art
- 11 March 2010
- journal article
- review article
- Published by Elsevier BV in Seminars in Immunology
- Vol. 22 (3), 105-112
- https://doi.org/10.1016/j.smim.2010.02.001
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantationProceedings of the National Academy of Sciences of the United States of America, 2009
- Oncogenic stress sensed by the immune system: role of natural killer cell receptorsNature Reviews Immunology, 2009
- A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomasBritish Journal of Cancer, 2009
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanomaThe Journal of Experimental Medicine, 2008
- Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical studyProceedings of the National Academy of Sciences of the United States of America, 2008
- Phase Ib Trial Assessing Autologous, Tumor-pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients With Metastatic MelanomaJournal of Immunotherapy, 2008
- Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic MelanomaJournal of Immunotherapy, 2008
- Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillanceProceedings of the National Academy of Sciences, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- The Hallmarks of CancerCell, 2000